
REVIEW

Sex Steroid Hormones in Depressive Disorders as a Basis for New Potential Treatment Strategies

Miriam PILLEROVÁ¹, Michal PASTOREK¹, Veronika BORBÉLYOVÁ¹, Vladimír RILJAK², Karyn M. FRICK³, Július HODOSY¹, Lubomíra TÓTHOVÁ¹

¹Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovak Republic, ²Institute of Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ³Department of Psychology, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin, USA

Received June 28, 2022

Accepted October 17, 2022

Summary

The sex steroid hormones (SSHs) such as testosterone, estradiol, progesterone, and their metabolites have important organizational and activational impacts on the brain during critical periods of brain development and in adulthood. A variety of slow and rapid mechanisms mediate both organizational and activational processes *via* intracellular or membrane receptors for SSHs. Physiological concentrations and distribution of SSHs in the brain result in normal brain development. Nevertheless, dysregulation of hormonal equilibrium may result in several mood disorders, including depressive disorders, later in adolescence or adulthood. Gender differences in cognitive abilities, emotions as well as the 2-3 times higher prevalence of depressive disorders in females, were already described. This implies that SSHs may play a role in the development of depressive disorders. In this review, we discuss preclinical and clinical studies linked to SSHs and development of depressive disorders. Our secondary aim includes a review of up-to-date knowledge about molecular mechanisms in the pathogenesis of depressive disorders. Understanding these molecular mechanisms might lead to significant treatment adjustments for patients with depressive disorders and to an amelioration of clinical outcomes for these patients. Nevertheless, the impact of SSHs on the brain in the context of the development of depressive disorders, progression, and treatment responsiveness is complex in nature, and depends upon several factors in concert such as gender, age, comorbidities, and general health conditions.

Key words

Affective disorders • Sex steroid receptors • Androgens • Brain structures • Molecular mechanism • Potential treatment strategy

Corresponding author

L. Tóthová, Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University, Sasinkova 4, 811 08 Bratislava, Slovak Republic. E-mail: lubomira.tothova@imbm.sk

Introduction

Depression is not a unitary concept. Depressive disorders are classified as affective disorders according to the Diagnostic and Statistical Manual of Mental Disorders 5 [1]. There are many forms of depression including major depressive disorder, persistent depressive disorder (dysthymia), peripartum (postpartum) depression, disruptive mood dysregulation disorder, psychotic and seasonal depression, and premenstrual dysphoric disorder [2-4]. According to the World Health Organization, depressive disorders are among the most common psychiatric disorders that affect humans of all ages, with an estimated 3.8 % of the population suffering from at least one form of depression (including 5.0 % among adults and 5.7 % among adults older than 60 years) [5]. Along with other affective disorders, depressive disorders represent a worldwide problem with both socio-economic and general health burdens [6-8]. Interestingly, a recent meta-analysis showed that

depressive disorders are 2-3 times more common in women than men, while no differences are reported among the age groups [9]. Such sex differences in the prevalence of depressive disorders implies the sex steroid hormones (SSHs) play at least some role in the development of depressive disorders.

SSHs, including androgens, estrogens, and progesterone (P4) are crucial during the development of various brain structures throughout the critical prenatal and perinatal periods. These critical periods are known as organizational windows and are characterized by the interaction of hormones with immature neurons. This results in permanent changes in the structure and thus function of the brain with subsequent gender differences in behavior [10,11]. The organizational effects can be seen mainly within perinatal growth when the brain is more prone to the structural alterations. There are several other periods well known for structural organization within the brain, i.e. during puberty and adolescence. These organizational changes in the structure are believed to be long-term and last through adulthood [12,13]. One of the most well-known changes due to early androgen presence of the so-called sexually dimorphic nucleus includes the medial preoptic area of the hypothalamus. Early exposure to testosterone (T) characteristically organizes (increased density of neurons, increased dendritic spine density) this area towards more masculine behavior in adulthood [11]. Another example includes androgen induced neurogenesis and enhanced new neuron survival in the hippocampus (HIP) [14]. The mechanism behind these changes includes decreased basal activity in the hypothalamo-pituitary-adrenal axis (HPA) [15]. The list of brain structures involved in brain organization due to androgens is broad and is reviewed elsewhere [16].

On the other hand, the same SSHs have additional activational effects on neurons, thus affecting physiology and behavior. More about activational effects is described in chapter 5. These changes depend on the actual SSHs concentration in blood, especially when considering hormonal cycles (i.e. diurnal, circatrigintan or annual). Therefore, activational effects are usually fast, reversible, and short-term [10,11]. Generally, activational effects can play a role mainly in adulthood once organizational processes in brain structures are over, acting independently as well as in combination with organizational effects [12]. Overall, the effect of imbalanced SSHs on brain can result in the development of depressive disorders. Therefore, both organizational

and activational effects of SSHs on the brain could affect behavioral outcomes later in life, particularly the development of depressive disorders [17,18].

Puberty and early adulthood are time periods with a high incidence of depressive disorders [7,19]. Aging is associated with SSHs concentration decline while on the other hand, the incidence of affective disorders and psychiatric syndromes increase. Though this is true for both, men and women [20], there is gender variability, indicating that females are approximately twice as prone to the development of depressive disorders when compared to males. Indeed, the females undergo more variation in the SSHs concentration, i.e. hormonal fluctuations during menstrual cycles, pregnancy, and after delivery, menopause, etc. [21]. Apart from such hormonal variation, it is believed that females are more prone to distress consequences, which may exacerbate affective disorder development [22]. Taken together, SSHs are significant regulators of cognitive functions and mood during prenatal/postnatal development but also in adulthood, and SSHs dysregulation may lead to the development of depressive disorders [23,24]. SSHs raised interest worldwide in terms of brain and behavior research for both animals [25-27] and humans [28-30]. In this review, we will focus on the role of SSHs in the context of depressive disorders *per se*, it will not include all disorders in which depressive syndrome may occur including for instance bipolar disorder, borderline personality disorder, etc.

Brain regions implicated in depressive disorders

Many brain regions are involved in depressive disorders including regions with higher functions related to stress response, memory formation, or emotion handling. The brain regions discussed in this review include the prefrontal cortex (PFC), amygdala (AMY), HIP, and hypothalamus (HYP). Implication of these brain regions can be gender specific [11,13]. Impairment of the structure or function of the PFC, AMY, HIP or HYP may result in affective disorders including depressive disorders [31].

The PFC manages cognitive functions related to executive decisions, social feeling [32,33] as well as self-control, self-esteem [34], and attention or planning [35,36]. Certainly, there are connections between the PFC and other brain regions, specifically to the AMY. This reciprocal link helps to regulate anxiety or fear in both

genders [37]. Apart from the interconnections with the PFC, the AMY plays a significant role in development of depressive disorders on its own. Fearful and threatening stimuli are processed and tagged for their emotional value in the AMY along with further emotional processing and adequate response [38-40]. Functional magnetic resonance imaging studies consider the AMY as one of the main structures involved in the development of depressive disorders and its treatment [41]. Spatial navigation, emotions, and HPA axis regulation are part of HIP functioning [42]. Moreover, the linkage of the ventral HIP to the AMY predisposes the HIP to take its part in contextual fear conditioning [43,44] and thus potentially in the development of depressive disorders. Lastly, the HYP is part of a major neuroendocrine system and HPA axis, together with the hypothalamus-pituitary-gonadal (HPG) axis, are implicated in stress response, hence they may contribute to the regulation of depressive disorders [45].

Several neuroimaging studies revealed that impairment to neural structures or pathways of any of the PFC, AMY, HIP or HYP, especially in the critical organizational periods, can lead to the development of depressive disorders later in adolescence or adulthood [46-48]. Additionally, depressive disorders may be a result of a disarrangement of emotional or cognitive centers in the PFC [47] or HYP [48]. These brain areas express SSHs receptors, both intracellular and membrane-associated androgen (AR), estrogen (ER α , ER β) or P4 receptors [49-52]. Recently, the transmembrane G-protein coupled estrogen receptor 1 (GPER1) has been found within the brain [53,54]. Also, the transmembrane receptor for androgen – Zinc transporter protein 9 (ZIP9), primarily found in the prostate, has also been detected in the brain [50,52].

As such, this review will discuss the perinatal influence of androgens, estrogens, and P4 on the PFC, AMY, HIP and HYP in the context of depressive disorders. Subsequently, the molecular mechanism of the pathogenesis of depressive disorders as well as the potential contribution of SSHs for new treatment strategies, will be reviewed.

Animal research

Depression-like behavior is assessed in laboratory rodents using various behavioral tests such as the forced swim test, tail suspension test, sucrose preference test [55], or novelty-induced hypophagia test

[56]. In males, the effect of physiological concentrations of prenatal T may also be associated with neurogenesis and increased dendritic spine density in the HIP. This was shown in male rats treated neonatally with an antagonist of AR, flutamide, and tested prior to puberty with the forced swim test and sucrose preference test, in which authors observed a significant increase in a depression-like behavior. Moreover, neonatal treatment with flutamide inhibited neurogenesis (microtubular associated protein-2 neurons in cornu ammonis 1 region, and dentate gyrus), as well as the formation and decrease in neuronal dendritic spine density in the cornu ammonis 1 region of pre-pubertal male rats. These results indicated the antidepressant and neuroprotective properties and organizational effects of T *via* AR in pre-adolescent male rats [57]. During studies on non-human primates, the determination of prenatal T is even more challenging. The second digit to fourth digit ratio (2D:4D) represents a potential proxy marker for prenatal androgen concentration. Digit ratio 2D:4D correlates negatively with fetal T and positively with fetal estrogens, therefore, males have usually lower ratio in comparison to females [58,59]. For example, the measurement of prenatal T exposure was determined by the 2D:4D digit ratio *via* X-ray imaging in female cynomolgus monkeys (*Macaca fascicularis*). The protective effect of physiological levels of prenatal T in female monkeys was observed. The longer 4th finger as well as lower 2D:4D ratio was observed in the control group in comparison to female monkeys with naturally occurring depression-like behavior [18]. These results indicate that higher 2D:4D ratio in females is positively correlated with depression-like behavior and so it may provide a predictive diagnostic tool for such behavior in non-human primates. The neuroprotective action of T in the HIP may include its ability to ameliorate the negative effects of stress or depression-like behavior and activate the signaling pathways leading to cellular growth, proliferation, and survival [60].

Human research

In children, prenatal and early postnatal dysregulation of T (lower salivary concentration) and cortisol (higher salivary concentration) represent a risk factor for affective disorder pathophysiology, especially in girls, who are more vulnerable to hormone dysregulation [61].

In boys, not only does the concentration of

prenatal T possibly influence depressive disorders but it also influences other components of the T signaling pathway, such as the genetic polymorphism of AR [62,63]. The importance of AR and its polymorphisms in the modulation of depressive disorders has been investigated in a clinical study that reported an association between CAG trinucleotide repeats in the AR gene and major depressive disorder in male children and adolescents. The length of CAG trinucleotide repeats, which codes the glutamine amino acid, is between 8-35 repetitions in healthy individuals. There is a negative correlation between the CAG repetitions and AR expression which negatively affect sensitivity and affinity to androgens [64-66]. A significant negative correlation between scores of the Center for Epidemiologic Studies Depression Scale and the Patient Health Questionnaire-9, that measure the severity of depressive symptoms, and the length of AR CAG repetitions, together with low salivary T, was found in male adolescents with major depressive disorder [62,63].

Genetic polymorphisms of the ER α gene play a significant role in the predisposition to depressive disorders in women. The genetic variant G allele (rs9340799) or C allele (rs2234693) of ER α have been specifically associated with an increased risk of recurrent depressive episodes in aged homozygous women (65 years old). In another study of ER α , the *PvuII* polymorphism of ER α appeared to be involved in the regulation of its expression. A significant positive association between *PvuII* ER α and major depressive disorder was found only in women subjects as compared to healthy women controls but not in depressed men compared to healthy men. This sex-different association may be another explanation to the twice-as-high level of susceptibility to depressive disorders in women [67]. In addition, genotype frequencies of single nucleotide polymorphisms in genes related to 17 β -estradiol (E2) synthesis or metabolism in women suffering from depressive disorders were studied, where different polymorphisms in different genes were associated with greater odds of depressive disorders in pre-/perimenopausal women from these ethnic groups: 1. Caucasian women with CC and AC genotype of rs2606345 polymorphism in cytochrome P450 (CYP) 1A1 gene compared to AA genotype (2-fold); 2. African American woman with CC genotype of rs2606345 polymorphism in CYP1A1 gene compared to AA genotype (10-fold); 3. Japanese women with TT genotype of rs936306 polymorphism in CYP 19 gene

compared to CC (5-fold), and CT (9.6-fold) genotypes; 4. Chinese women with TT genotype of rs615942 polymorphism in 17HSD gene compared to GT (11-fold) and GG (>7-fold) genotypes [68].

To conclude, there is a very important genetic factor that affects the impact of SSHs on early brain development. Genetic variants of SSHs receptors or the polymorphisms of genes involved in SSHs signaling influence the effect of prenatal SSHs in both women and men. Certain polymorphisms in AR (CAG repetitions) or ER α (allele variant) may contribute to the development or the pathophysiology of depressive disorders in humans.

Regulation of depression-like behavior by SSHs and molecular interactions

In multiple animal and human studies, the antidepressant effects of SSHs were observed through classical signaling pathways of SSHs receptors such as the AR [69], ER β [70], and P4 receptors [26,71]. However, non-classical signaling *via* transmembrane receptors such as GPER1 also appears to play a significant role in the pathophysiology of depressive disorders in both animals [17,72] and humans [73]. The relationship between the transmembrane AR ZIP9 and depressive disorders has not yet been described. Nevertheless, its expression has been detected not only in the gonads but also in the brain [51] suggesting a potential role of AR ZIP9 receptors in the development of affective disorders but this is the subject of future research.

SSHs receptors-related pathways in animal studies

The major signaling pathway of T in the development and progression of depressive disorders may be through AR. Intracellular AR deficiency exaggerates depression-like behavior in both male and female mice in sucrose preference and forced swim tests through brain-derived neurotrophic factor (BDNF) modulation in the chronic mild stress model of depression [74]. There is evidence that AR deficiency in male mice accelerates the development of depression-like behavior in a mouse model *via* altering miR-204-p3/BDNF/protein kinase B/mitogen-activated protein kinase signaling pathways in the HIP [74]. Regarding the activational effects of T on depression-like behavior, treatments with physiological levels of T reversed depression-like behavior in socially isolated and gonadectomized adult male rats in sucrose

preference and novelty-induced hypophagia tests [56].

On the other hand, primiparous female rats also exhibit higher depression-like behavior 3 weeks postpartum, with recovery at 5 or 10 weeks postpartum compared with nulliparous females in the diestrus phase of the menstrual cycle. These behavioral changes were associated with lower ER α but not ER β expression in the medial AMY. These results indicate that E2 *via* ER α signaling in the medial AMY may be responsible for the onset of depression-like behavior, at least in postpartum rats [75].

In nulliparous ovariectomized mice, lower depression-like behavior is the result of activation of ER β but not ER α . This suggests an antidepressant effect of E2 *via* classical ER β signaling pathways [76,77]. Similarly, lower depression-like behavior in the forced swim test was observed in ovariectomized rats following administration of ER β selective modulators into the HIP [78]. These mechanisms are mediated predominantly by ER β , but not by ER α signaling pathways in the HIP of ovariectomized mice [70,79]. In addition, ER β signaling is involved in NACHT, LRR and PYD domains-containing protein 3 regulation, which may decrease depression-like behavior in ovariectomized mice [80].

Apart from “classic” signaling using ER α and ER β , antidepressant-like effects of E2 might also be stimulated through the non-classical GPER1 pathway. This is supported by an experiment, wherein aged female rats were injected with GPER1 agonists such as G-1 (1-[4-(6-bromobenzo[1,3] dioxol-5yl)-3a,4,5,9b-tetra-hydro-3H-cyclopenta [c] quinolin-8-yl]-ethanone), E2, diarylpropionitrile, and subsequently tested in forced swim test, in which the rats spent significantly less time immobile compared to control rats. Moreover, G-1 enhanced hippocampal antioxidant capacity and stimulated the expression of ER α and ER β [81]. GPER1 is also responsible for the inhibition of mitochondrial permeability transition pore opening and improvement of cardiac function through activation of mitogen-activated protein kinase signaling, which suggests its potential protective role in the brain [82]. Additionally, reduction of GPER1 or its impaired signaling during prenatal periods lead to depression-like behavior later in life [17]. Similarly, intracerebroventricular administration of the GPER1 antagonist G15 ((3aS*,4R*,9bR*)-4-(6-Bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta [c] quinoline), as well as genetic deletion of the GPER1 gene, in ovariectomized rats resulted in depression-like behavior in forced swim tests [72]. The

antidepressant effects of GPER1 signaling might be mediated through protein kinase A signaling which further elevates translocation, protein phosphorylation, and normalizes the redox status in menopausal rats [72]. Moreover, prenatal reduction of GPER1 or its impaired signaling results in depression-like behavior in both female and male mice [17]. Results from these experiments indicate the neuroprotective and antidepressant-like effects of the GPER1 agonist G-1 and should be considered in the pathophysiology of depressive disorders.

Non-SSHs receptors-related pathways in animal studies

Lastly, ciliary neurotrophic factor (CNTF) has a key sex-specific role in the regulation of depression-like behavior in mice. Wild-type (WT) CNTF^{+/+} female mice exhibit higher depression-like behavior compared to WT CNTF^{+/+} male mice. Alternatively, CNTF^{-/-} females exhibit lower depression-like behavior (reduced immobility time) compared to CNTF^{-/-} males (higher immobility time) in the forced swim test. The sex-specific role of CNTF in the regulation of depression-like behavior was also confirmed by higher CNTF expression in WT CNTF^{+/+} females than WT CNTF^{+/+} male mice. Furthermore, P4 treatment reduced the expression of CNTF in the AMY of CNTF^{+/+} females but not in CNTF^{-/-} females. This study indicates relatively new sex-specific treatments for depression-like behavior, such as P4 in females and CNTF-stimulating drugs in males [83]. On top of that, several studies have examined the potential contribution of allopregnanolone (ALLO), which is a neuroactive metabolite of P4, in depression [84,85]. ALLO can be employed not only as a transcription factor, but also as a modulator of neuronal excitability by binding to the steroid binding site on the GABA A receptor [86]. In the HIP of female proestrus rats, high ALLO concentrations appear to have antidepressant-like effects [87]. The role of the neuroactive steroid ALLO in depression-like behavior is associated with an elevation of BDNF/tropomyosin receptor kinase (Trk) B signaling in the HIP or PFC [85,88], activation of dopamine receptor-2, stimulation of glutamate neurotransmission, and increased Ca²⁺ release in both male and female rodents [85,89]. These molecular changes appear to be necessary for ALLO to provide antidepressant-like effects, however, this association provides only circumstantial evidence for a causal relationship. The molecular mechanisms are summarized in Figure 1.




Fig. 1. Molecular mechanisms behind depression-like behavior in female and male rodents. AR – androgen receptor, ER α – estrogen receptor alpha, AMY – amygdala, HIP – hippocampus, GPER1 – G-protein-coupled estrogen receptor 1, CNTF – ciliary neurotrophic factor, GABA A – gamma-aminobutyric acid A, BDNF/TrkB – brain-derived neurotrophic factor/tropomyosin related kinase B, DR2 – dopamine receptor 2. Created with BioRender.com.

SSHs receptors-related pathways in human postmortem studies

The HYP and HIP are involved in depressive disorders through the HPA axis, which is a primary neuroendocrine system activated in stress situations. The pathway starts with increased corticotropin-releasing hormone release from the paraventricular nucleus of the HYP ending with cortisol release from the adrenal glands [90]. Estrogen-responsive elements are responsible for the beginning of the corticotropin-releasing hormone gene transcription [91], while androgen-responsive elements repress it. T is also believed to stop HPA activity [92]. In contrast, E2 likely activates the HPA axis *via* ER α [91]. Impaired equilibrium in receptor expression could interfere with the activation of the HPA axis in patients with depressive disorders.

GPER1 concentration in serum is higher in patients with major depressive disorder (18-50 years old) when compared to age-matched controls. Moreover, the authors found a positive correlation between the concentration of GPER1 in serum and depression scores. Elevated GPER1 concentration in serum was accurate in predicting the presence of depressive disorders and could be a candidate for a peripheral biomarker in generalized depressive disorders in both women and men [73]. These results are contradictory to the results from animal research, where reduction in GPER1 leads to higher

depression-like behavior. The main reason for those discrepancies may be that the human study was limited to a small number of patients (34 women, 22 men) which also included only fertile individuals. Moreover, the cross-sectional design of human study limited obtained data. The GPER1 concentration in serum before and after treatment were missing. In rodent studies, animals are in controlled conditions, where the researchers may control the estrous/T diurnal cycles by ovariectomy/gonadectomy. Moreover, the role of GPER1 may be tested using various experimental designs involving GPER1 antagonists/agonists, knockout mice, and multiple molecular analyses of rodent tissue, which is not possible in human studies. Further studies need to be done to clarify the role of GPER1 in major depressive disorder in humans.

Non-SSHs receptors-related pathways in human postmortem studies

Regarding organizational changes of the brain during critical periods, BDNF is an important factor. It is responsible for the development, differentiation, and survival of neurons, growth of neurites, synaptic plasticity, synthesis of differentiating factors, and homeostasis, as well as modulation of affective-related behaviors [93-95]. Interestingly, a recent study showed, that a single nucleotide polymorphism of the BDNF gene

(Val66Met) appears to be implicated in the development of major depressive disorder more in men than women [96]. Another factor, the nerve growth factor (NGF), is a growth factor similar to BDNF. NGF is necessary for sympathetic and sensory neuron survival and maintenance, and is involved in the regulation of stress responses *via* the HPA axis [97,98]. Post-mortem studies of suicidal patients [99] or patients with major depressive disorder [100-102] showed morphological (e.g. cellular death, lower neurogenesis, and smaller neuron soma size)

as well as molecular changes (e.g. reduced BDNF/TrkB and NGF/TrkA) in the HIP [103] suggesting that not only BDNF/TrkB signaling but also NGF/TrkA appears to be involved in pathophysiology as well as treatment for depressive disorders. SSHs such as T, E2, and P4 are implicated in the regulation of BDNF or NGF through which they may provide neuroprotection, neuron survival, and also antidepressant effects (Fig. 2) in human [96,101,102,104,105] and animal studies [79,88, 106-108].




Fig. 2. Molecular mechanisms behind depressive disorders in women and men. AR – androgen receptor, ER α – estrogen receptor alfa, HIP – hippocampus, HYP – hypothalamus, CRH – corticotropin-releasing hormone, BDNF/TrkB – brain-derived neurotrophic factor/tropomyosin related kinase B, NGF/TrkA – nerve growth factor/tropomyosin receptor kinase A. Created with BioRender.com.

Where are we in clinical research?

Probably the best example is the postpartum depression. Recently, the Food and Drug Administration office approved intravenous ALLO treatment (brexanolone injections) for the treatment of postpartum depression in women [109]. The Food and Drug Administration office approved this medication based on the positive results from the 3 phases of clinical trials focused on safety and efficacy of brexanolone use for the treatment of moderate to severe post-partum depression [110]. The role of ALLO – the positive allosteric modulators of GABA A receptors in humans, is in motivation for the promotion of social contact. ALLO is increased during stress responses in humans [111]. In a pilot study, the expression of the enzyme converting P4 into ALLO – 5 α -reductase 1, was examined in the PFC (Brodmann's area 9) of patients with depressive

disorders. In depressed patients, the expression of 5 α -reductase mRNA was approximately 3-times lower in comparison to healthy subjects. However, ALLO concentrations increased in depressed subjects after treatment with selective serotonin reuptake inhibitors or tricyclic antidepressants compared to non-treated depressed subjects [112]. Moreover, the concentration of ALLO was lower in the cerebrospinal fluid of patients with depressive disorders [113]. ALLO is considered one of the most potent SSHs with anti-depressant effects [114,115]. Several clinical studies are testing drugs that have potential anti-depressant effects *via* ALLO, such as fluoxetine [116,117], fluvoxamine [117], mirtazapine [118], olanzapine [119], carbamazepine [120,121], and brexanolone [122-124]. Another potential target for depressive disorder treatment related to the synthesis of ALLO appears to be the translocation protein, which is located on the outer mitochondrial membrane and

transports the cholesterol onto the inner mitochondrial membrane [85,125]. These studies of antidepressant drugs demonstrate the pharmacological effects and therapeutic potential of ALLO for the treatment of depressive disorders in humans [89].

In men, age-associated T deficiency (its concentrations in plasma declines for approximately 0.11 nmol/l each year after the age of 30) is strictly not comparable to women during menopause, although there is some overlap in its effect on mental health, i.e. it may lead to affective disorders including depressive disorders [126]. Clinically significant depressive symptomatology was also observed in 92.4 % of hypogonadal men (20-80 years-old). These symptoms were improved after 3 months of T replacement therapy and this improvement was maintained after 12-months in subcohort of less than 60-years-old patients [127]. Systematic reviews and meta-analysis of the antidepressant effects of T revealed significantly positive effects of T therapy in patients with depressive symptoms (men, 18-70 years old). Furthermore, the most efficient route of administration appeared to be the application of T gel [128]. However, a positive correlation between higher concentrations of T and anti-depressant effects is not broadly supported because of conflicting results from some controlled and randomized trials, discussed in the review [109,116-124]. The authors concluded that T therapy may have anti-depressant effects in specific populations such as men with early onset depressive disorders, hypogonadal men, or in men who are resistant to antidepressant drugs [129]. In another study, the group of patients that were more responsive to T treatment included hypogonadal men and middle-aged men with less severe depression or treatment for refractory depression [130]. Furthermore, T replacement therapy improves depressive symptoms in adult men who suffer from the type of depression with late-onset T deficiency; however, it is not an effective treatment in patients with major depressive disorder [131]. These results indicate that T should not be considered as a universal treatment for depressive disorders in men, but rather as a treatment with antidepressant effects in groups with certain health condition such as men with hypogonadism or with HIV/AIDS.

Conclusions

The high prevalence of depressive disorders warrants the search for additional pathophysiology

processes to understand the basis of the disease along with potential novel therapies apart from standard therapy. Given the differences in the incidence of depressive disorders between females and males, the SSHs with their organizational and activational effects on brain structures [16] play a role in mood modulation. However, the metabolism of SSHs and neurosteroids is complex with a variety of activated membrane and/or intracellular receptors. Apart from AR and ER β activation, GPER1, BDNF/TrkB signaling, and GABA A receptors within the serotonergic system can be implicated in both females and males and have a huge therapeutic potential. Those pathways should be considered in possible future treatment targets for research in the context of depressive disorders.

In conclusion, the studies discussed in this review indicate that SSHs and their metabolites (mainly ALLO) play a major role in the development of depressive disorders but their effect depends on the gender, age, comorbidities, general health condition, and the type of depressive disorder. The current state of the research does not allow us to conclude with a specific answer on which SSHs/pathway should be used as a treatment for depressive disorders but rather shows us the directions for future research. Future experiments should investigate the possible treatment strategies involving ALLO signaling *via* GABA A receptor, E2 signaling *via* GPER1, or BDNF/TrkB signaling alone or in combination with currently available treatment (selective serotonin reuptake inhibitors/tricyclic antidepressants). Specific types of depressive disorders as well as gender, age and health conditions should also be considered in experimental designs. Various combination strategies thus ought to be developed so as to bolster the positive mental health of both males and females.

Conflict of Interest

There is no conflict of interest.

Funding

This study was supported by grants from SAIA NSP scholarship, the Tatra bank grant, Comenius University grant UK/14/2022 Slovak Research and Development Agency No. APVV-20-0185, APVV-20-0472 and National Institutes of Health (USA) grants R01MH107886. Institutional support was provided by PROGRES Q35/LF1/2 project by Charles University.

Acknowledgements

We thank Thomas T. Lovely, George W. Sande, and Lisa R. Taxier for proofreading the manuscript for us in the English language.

Abbreviations

2D:4D – second digit to fourth digit ratio, ALLO – allopregnanolone, AMY – amygdala, AR – androgen receptor, BDNF – brain-derived neurotrophic factor, CNTF – ciliary neurotrophic factor, CYP – cytochrome

P450, E2 – estradiol, ER – estrogen receptor, GABA – gamma-aminobutyric acid, GPER1 – G-protein coupled estrogen receptor 1, HIP – hippocampus, HPA – hypothalamus-pituitary-adrenal axis, HPG – hypothalamus-pituitary-gonadal, HYP – hypothalamus, NGF – nerve growth factor, P4 – progesterone, PFC – prefrontal cortex, SSHs – sex steroid hormones, T – testosterone, TrkA – tropomyosin receptor kinase A, TrkB – tropomyosin receptor kinase B, WT – wild-type, ZIP9 – zinc transporter protein 9.

References

1. American Psychiatric Association: Mood disorder. In: *Diagnostic and Statistical Manual of Mental Disorders (DSM-5)*. 5th ed Washington, DC, 2013. <https://doi.org/10.1176/appi.books.9780890425596>
2. Ellenbroek B, Youn J: Affective Disorders. In: *Gene-Environment Interactions in Psychiatry: Nature, Nurture, Neuroscience*. Academic Press, 2016, pp 173-231. <https://doi.org/10.1016/B978-0-12-801657-2.00007-0>
3. Temin P: Great Depression. In: *Banking Crises*. JONES G (ed.), Palgrave Macmillan, London, 2016, pp 144-153. https://doi.org/10.1057/9781137553799_16
4. LeMoult J, Gotlib IH. Depression: A cognitive perspective. *Clin Psychol Rev* 2019;69:51-66. <https://doi.org/10.1016/j.cpr.2018.06.008>
5. Lim GY, Tam WW, Lu Y, Ho CS, Zhang MW, Ho RC. Prevalence of depression in the community from 30 countries between 1994 and 2014. *Sci Rep* 2018;1:2861. <https://doi.org/10.1038/s41598-018-21243-x>
6. Murrell SA, Himmelfarb S, Wright K. Prevalence of depression and its correlates in older adults. *Am J Epidemiol* 1983;2:173-185. <https://doi.org/10.1093/oxfordjournals.aje.a113528>
7. Gater R, Tansella M, Korten A, Tiemens BG, Mavreas VG, Olatawura MO. Sex differences in the prevalence and detection of depressive and anxiety disorders in general health care settings: report from the World Health Organization Collaborative Study on Psychological Problems in General Health Care. *Arch Gen Psychiatry* 1998;5:405-413. <https://doi.org/10.1001/archpsyc.55.5.405>
8. Charlson F, van Ommeren M, Flaxman A, Cornett J, Whiteford H, Saxena S. New WHO prevalence estimates of mental disorders in conflict settings: a systematic review and meta-analysis. *Lancet* 2019;10194:240-248. [https://doi.org/10.1016/S0140-6736\(19\)30934-1](https://doi.org/10.1016/S0140-6736(19)30934-1)
9. Albert PR. Why is depression more prevalent in women? *J Psychiatry Neurosci* 2015;4:219-221. <https://doi.org/10.1503/jpn.150205>
10. Williams CL. A reevaluation of the concept of separable periods of organizational and activational actions of estrogens in development of brain and behavior. *Ann N Y Acad Sci* 1986;282-292. <https://doi.org/10.1111/j.1749-6632.1986.tb28019.x>
11. Cooke B, Hegstrom CD, Villeneuve LS, Breedlove SM. Sexual differentiation of the vertebrate brain: principles and mechanisms. *Front Neuroendocrinol* 1998;4:323-362. <https://doi.org/10.1006/frne.1998.0171>
12. Schulz KM, Sisk CL. The organizing actions of adolescent gonadal steroid hormones on brain and behavioral development. *Neurosci Biobehav Rev* 2016;70:148-158. <https://doi.org/10.1016/j.neubiorev.2016.07.036>
13. Vigil P, Del Río JP, Carrera B, ArÁnguiz FC, Rioseco H, Cortés ME. Influence of sex steroid hormones on the adolescent brain and behavior: An update. *Linacre Q* 2016;3:308-329. <https://doi.org/10.1080/00243639.2016.1211863>
14. Blankers SA, Galea LAM. Androgens and adult neurogenesis in the hippocampus. *Androg Clin Res Ther* 2021;1:203-215. <https://doi.org/10.1089/andro.2021.0016>
15. Pivina SG, Akulova VK, Ordyan NE. Characteristics of behavior and stress reactivity of the hypophyseal-adrenocortical system in rats with prenatal inhibition of testosterone metabolism. *Neurosci Behav Physiol* 2007;1:53-58. <https://doi.org/10.1007/s11055-007-0149-6>

16. Filová B, Ostatníková D, Celec P, Hodosy J. The effect of testosterone on the formation of brain structures. *Cells Tissues Organs* 2013;3:169-177. <https://doi.org/10.1159/000345567>
17. Kajta M, Wnuk A, Rzemieniec J, Litwa E, Lason W, Zelek-Molik A, Nalepa I, Rogóż Z, Grochowalski A, Wojtowicz AK. Depressive-like effect of prenatal exposure to DDT involves global DNA hypomethylation and impairment of GPER1/ESR1 protein levels but not ESR2 and AHR/ARNT signaling. *J Steroid Biochem Mol Biol* 2017;171:94-109. <https://doi.org/10.1016/j.jsbmb.2017.03.001>
18. Li W, Luo L-Y, Yang X, He Y, Lian B, Qu C-H, Wu Q-Y, Zhang J-G, Xie P. Depressed female cynomolgus monkeys (*Macaca fascicularis*) display a higher second-to-fourth (2D:4D) digit ratio. *Zool Res* 2019;3:219-225. <https://doi.org/10.24272/j.issn.2095-8137.2019.022>
19. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen H-U, Kendler KS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. *Arch Gen Psychiatry* 1994;1:8-19. <https://doi.org/10.1001/archpsyc.1994.03950010008002>
20. Mendell AL, MacLusky NJ. Neurosteroid metabolites of gonadal steroid hormones in neuroprotection: implications for sex differences in neurodegenerative disease. *Front Mol Neurosci* 2018;11:359. <https://doi.org/10.3389/fnmol.2018.00359>
21. Solomon MB, Herman JP. Sex differences in psychopathology: of gonads, adrenals and mental illness. *Physiol Behav* 2009;2:250-258. <https://doi.org/10.1016/j.physbeh.2009.02.033>
22. Nolen-Hoeksema S, Larson J, Grayson C. Explaining the gender difference in depressive symptoms. *J Pers Soc Psychol* 1999;5:1061-1072. <https://doi.org/10.1037/0022-3514.77.5.1061>
23. Montgomery JC, Brincat M, Tapp A, Appleby L, Versi E, Fenwick PBC, Studd JWW. Effect of oestrogen and testosterone implants on psychological disorders in the climacteric. *Lancet* 1987;8528:297-299. [https://doi.org/10.1016/S0140-6736\(87\)92026-5](https://doi.org/10.1016/S0140-6736(87)92026-5)
24. Fink G, Sumner B, Rosie R, Wilson H, McQueen J. Androgen actions on central serotonin neurotransmission: relevance for mood, mental state and memory. *Behav Brain Res* 1999;1:53-68. [https://doi.org/10.1016/S0166-4328\(99\)00082-0](https://doi.org/10.1016/S0166-4328(99)00082-0)
25. Galea LAM, Wide JK, Barr AM. Estradiol alleviates depressive-like symptoms in a novel animal model of post-partum depression. *Behav Brain Res* 2001;1:1-9. [https://doi.org/10.1016/S0166-4328\(01\)00170-X](https://doi.org/10.1016/S0166-4328(01)00170-X)
26. Frye C, Walf A, Rhodes M, Harney J. Progesterone enhances motor, anxiolytic, analgesic, and antidepressive behavior of wild-type mice, but not those deficient in type 1 5alpha-reductase. *Brain Res* 2004;1004:116-124. <https://doi.org/10.1016/j.brainres.2004.01.020>
27. Walf AA, Frye CA. Estradiol reduces anxiety- and depression-like behavior of aged female mice. *Physiol Behav* 2010;2:169-174. <https://doi.org/10.1016/j.physbeh.2009.09.017>
28. Miller KK, Wexler TL, Zha AM, Lawson EA, Meenaghan EM, Misra M, Binstock AB, Herzog DB, Klibanski A. Androgen deficiency: association with increased anxiety and depression symptom severity in anorexia nervosa. *J Clin Psych* 2007;6:959-965. <https://doi.org/10.4088/JCP.v68n0621>
29. Chaudhari AP, Mazumdar K, Mehta PD. Anxiety, depression, and quality of life in women with polycystic ovarian syndrome. *Indian J Psychol Med* 2018;3:239-246. https://doi.org/10.4103/IJPSYM.IJPSYM_561_17
30. Gordon JL, Peltier A, Grummisch JA, Sykes Tottenham L. Estradiol fluctuation, sensitivity to stress, and depressive symptoms in the menopause transition: a pilot study. *Front Psychol* 2019;10:1319. <https://doi.org/10.3389/fpsyg.2019.01319>
31. Goldstein JM, Seidman LJ, Horton NJ, Makris N, Kennedy DN, Caviness VS, Jr., Faraone SV, Tsuang MT. Normal sexual dimorphism of the adult human brain assessed by in vivo magnetic resonance imaging. *Cereb Cortex* 2001;6:490-497. <https://doi.org/10.1093/cercor/11.6.490>
32. Goldman-Rakic PS, Cools AR, Srivastava K, Roberts AC, Robbins TW, Weiskrantz L. The prefrontal landscape: implications of functional architecture for understanding human mentation and the central executive. *Philos Trans R Soc Lond B Biol Sci* 1996;1346:1445-1453. <https://doi.org/10.1098/rstb.1996.0129>
33. Teffer K, Semendeferi K: Human prefrontal cortex: Evolution, development, and pathology. In: *Progress in Brain Research*. HOFMAN MA, FALK D (eds), Elsevier, 2012, pp 191-218. <https://doi.org/10.1016/B978-0-444-53860-4.00009-X>

34. Miller EK, Cohen JD. An integrative theory of prefrontal cortex function. *Annu Rev Neurosci* 2001;1:167-202. <https://doi.org/10.1146/annurev.neuro.24.1.167>
35. Funahashi S, Bruce CJ, Goldman-Rakic PS. Dorsolateral prefrontal lesions and oculomotor delayed-response performance: evidence for mnemonic "scotomas". *J Neurosci* 1993;4:1479-1497. <https://doi.org/10.1523/JNEUROSCI.13-04-01479.1993>
36. Gabrieli JDE, Poldrack RA, Desmond JE. The role of left prefrontal cortex in language and memory. *Proc Natl Acad Sci U S A* 1998;3:906. <https://doi.org/10.1073/pnas.95.3.906>
37. Guadagno A, Belliveau C, Mechawar N, Walker C-D. Effects of early life stress on the developing basolateral amygdala-prefrontal cortex circuit: the emerging role of local inhibition and perineuronal nets. *Front Hum Neurosci* 2021;15:669120. <https://doi.org/10.3389/fnhum.2021.669120>
38. Feldman S, Conforti N, Weidenfeld J. Limbic pathways and hypothalamic neurotransmitters mediating adrenocortical responses to neural stimuli. *Neurosci Biobehav Rev* 1995;2:235-240. [https://doi.org/10.1016/0149-7634\(94\)00062-6](https://doi.org/10.1016/0149-7634(94)00062-6)
39. Öhman A. The role of the amygdala in human fear: Automatic detection of threat. *Psychoneuroendocrinology* 2005;10:953-958. <https://doi.org/10.1016/j.psyneuen.2005.03.019>
40. Baxter MG, Crosson PL. Facing the role of the amygdala in emotional information processing. *Proc Natl Acad Sci U S A* 2012;52:21180. <https://doi.org/10.1073/pnas.1219167110>
41. Höfer P, Lanzenberger R, Kasper S. Testosterone in the brain: Neuroimaging findings and the potential role for neuropsychopharmacology. *Eur Neuropsychopharmacol* 2013;2:79-88. <https://doi.org/10.1016/j.euroneuro.2012.04.013>
42. Papadimitriou A, Priftis KN. Regulation of the hypothalamic-pituitary-adrenal axis. *Neuroimmunomodulation* 2009;5:265-271. <https://doi.org/10.1159/000216184>
43. Sheline YI, Mittler BL, Mintun MA. The hippocampus and depression. *Eur Psychiatry* 2002;S3:300s-305s. [https://doi.org/10.1016/S0924-9338\(02\)00655-7](https://doi.org/10.1016/S0924-9338(02)00655-7)
44. Campbell M, Jialal I. *Physiology, Endocrine Hormones*. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022.
45. Anand KS, Dhikav V. Hippocampus in health and disease: An overview. *Ann Ind Acad Neurol* 2012;4:239-246. <https://doi.org/10.4103/0972-2327.104323>
46. Stevens JS, Hamann S. Sex differences in brain activation to emotional stimuli: A meta-analysis of neuroimaging studies. *Neuropsychologia* 2012;7:1578-1593. <https://doi.org/10.1016/j.neuropsychologia.2012.03.011>
47. Varidaki A, Mohammad H, Coffey ET: Molecular mechanisms of depression. In: *Systems Neuroscience in Depression*. FRODL T (ed.), Academic Press, 2016, pp 143-178. <https://doi.org/10.1016/B978-0-12-802456-0.00005-4>
48. Hare BD, Duman RS. Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions. *Mol Psychiatry* 2020;11:2742-2758. <https://doi.org/10.1038/s41380-020-0685-9>
49. Guerra-Araiza C, Coyoy-Salgado A, Camacho-Arroyo I. Sex differences in the regulation of progesterone receptor isoforms expression in the rat brain. *Brain Res Bull* 2002;2:105-109. [https://doi.org/10.1016/S0361-9230\(02\)00845-6](https://doi.org/10.1016/S0361-9230(02)00845-6)
50. Foster TC. Role of estrogen receptor alpha and beta expression and signaling on cognitive function during aging. *Hippocampus* 2012;4:656-669. <https://doi.org/10.1002/hipo.20935>
51. Berg AH, Rice CD, Rahman MS, Dong J, Thomas P. Identification and characterization of membrane androgen receptors in the ZIP9 zinc transporter subfamily: I. Discovery in female atlantic croaker and evidence ZIP9 mediates testosterone-induced apoptosis of ovarian follicle cells. *Endocrinology* 2014;11:4237-4249. <https://doi.org/10.1210/en.2014-1198>
52. Almey A, Milner TA, Brake WG. Estrogen receptors in the central nervous system and their implication for dopamine-dependent cognition in females. *Horm Behav* 2015;125-138. <https://doi.org/10.1016/j.yhbeh.2015.06.010>
53. Pérez SE, Chen EY, Mufson EJ. Distribution of estrogen receptor alpha and beta immunoreactive profiles in the postnatal rat brain. *Dev Brain Res* 2003;1:117-139. [https://doi.org/10.1016/S0165-3806\(03\)00223-2](https://doi.org/10.1016/S0165-3806(03)00223-2)
54. Gorelick DA, Watson W, Halpern ME. Androgen receptor gene expression in the developing and adult zebrafish brain. *Dev Dyn* 2008;10:2987-2995. <https://doi.org/10.1002/dvdy.21700>

55. Belovicova K, Bogi E, Csatosova K, Dubovicky M. Animal tests for anxiety-like and depression-like behavior in rats. *Interdiscip Toxicol* 2017;1:40-43. <https://doi.org/10.1515/intox-2017-0006>
56. Carrier N, Kabbaj M. Testosterone and imipramine have antidepressant effects in socially isolated male but not female rats. *Horm Behav* 2012;5:678-685. <https://doi.org/10.1016/j.yhbeh.2012.03.001>
57. Zhang JM, Tonelli L, Regenold WT, McCarthy MM. Effects of neonatal flutamide treatment on hippocampal neurogenesis and synaptogenesis correlate with depression-like behaviors in preadolescent male rats. *Neuroscience* 2010;1:544-554. <https://doi.org/10.1016/j.neuroscience.2010.03.029>
58. Manning J, Kilduff L, Cook C, Crewther B, Fink B. Digit ratio (2D: 4D): a biomarker for prenatal sex steroids and adult sex steroids in challenge situations. *Front Endocrinol (Lausanne)* 2014;5:9. <https://doi.org/10.3389/fendo.2014.00009>
59. Ventura T, Gomes MC, Pita A, Neto MT, Taylor A. Digit ratio (2D:4D) in newborns: Influences of prenatal testosterone and maternal environment. *Early Hum Dev* 2013;2:107-112. <https://doi.org/10.1016/j.earlhumdev.2012.08.009>
60. McHenry J, Carrier N, Hull E, Kabbaj M. Sex differences in anxiety and depression: role of testosterone. *Front Neuroendocrinol* 2014;1:42-57. <https://doi.org/10.1016/j.yfrne.2013.09.001>
61. Black SR, Goldstein BL, Klein DN. Parental depression moderates the relationships of cortisol and testosterone with children's symptoms. *J Affect Disord* 2019;251:42-51. <https://doi.org/10.1016/j.jad.2019.01.047>
62. Su Q-R, Su L-Y, Su H-R, Chen Q, Ren G-Y, Yin YOU, Shen S-Q, Yu A-Y, Xia G-Y. Polymorphisms of androgen receptor gene in childhood and adolescent males with first-onset major depressive disorder and association with related symptomatology. *Int J Neurosci* 2007;7:903-917. <https://doi.org/10.1080/00207450600910689>
63. Sankar JS, Hampson E. Testosterone levels and androgen receptor gene polymorphism predict specific symptoms of depression in young men. *Gend Med* 2012;4:232-243. <https://doi.org/10.1016/j.genm.2012.05.001>
64. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. *Nucleic Acids Res* 1994;15:3181-3186. <https://doi.org/10.1093/nar/22.15.3181>
65. Tut TG, Ghadessy FJ, Trifiro M, Pinsky L, Yong E. Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. *J Clin Endocrinol Metab* 1997;11:3777-3782. <https://doi.org/10.1210/jc.82.11.3777>
66. Möhlig M, Arafat AM, Osterhoff MA, Isken F, Weickert MO, Spranger J, Pfeiffer AF, Schöfl C. Androgen receptor CAG repeat length polymorphism modifies the impact of testosterone on insulin sensitivity in men. *Europ J Endocrinol* 2011;6:1013. <https://doi.org/10.1530/EJE-10-1022>
67. Tsai S-J, Wang Y-C, Hong C-J, Chiu H-J. Association study of oestrogen receptor α gene polymorphism and suicidal behaviours in major depressive disorder. *Psychiatr Genet* 2003;1:19-22. <https://doi.org/10.1097/00041444-200303000-00003>
68. Kravitz HM, Janssen I, Lotrich FE, Kado DM, Bromberger JT. Sex steroid hormone gene polymorphisms and depressive symptoms in women at midlife. *Am J Med* 2006;119(9 Suppl 1):S87-S93. <https://doi.org/10.1016/j.amjmed.2006.07.010>
69. Seidman SN, Araujo AB, Roose SP, McKinlay JB. Testosterone level, androgen receptor polymorphism, and depressive symptoms in middle-aged men. *Biol Psychiatry* 2001;5:371-376. [https://doi.org/10.1016/S0006-3223\(01\)01148-9](https://doi.org/10.1016/S0006-3223(01)01148-9)
70. Chhibber A, Woody SK, Karim Rumi MA, Soares MJ, Zhao L. Estrogen receptor β deficiency impairs BDNF-5-HT(2A) signaling in the hippocampus of female brain: A possible mechanism for menopausal depression. *Psychoneuroendocrinology* 2017;82:107-116. <https://doi.org/10.1016/j.psyneuen.2017.05.016>
71. Schüle C, Eser D, Baghai TC, Nothdurfter C, Kessler JS, Rupprecht R. Neuroactive steroids in affective disorders: target for novel antidepressant or anxiolytic drugs? *Neuroscience* 2011;191:55-77. <https://doi.org/10.1016/j.neuroscience.2011.03.025>
72. Wang J, Li H-Y, Shen S-Y, Zhang J-R, Liang L-F, Huang H-J, Li B, Wu G-C, Zhang Y-Q, Yu J. The antidepressant and anxiolytic effect of GPER on translocator protein (TSPO) via protein kinase a (PKA) signaling in menopausal female rats. *J Steroid Biochem Mol Biol* 2021;207:105807. <https://doi.org/10.1016/j.jsbmb.2020.105807>

73. Findikli E, Kurutas EB, Camkurt MA, Karaaslan MF, Izci F, Fındıklı HA, Kardaş S, Dag B, Altun H. Increased serum G protein-coupled estrogen receptor 1 levels and its diagnostic value in drug naïve patients with major depressive disorder. *Clin Psychopharmacol Neurosci* 2017;4:337-342. <https://doi.org/10.9758/cpn.2017.15.4.337>
74. Hung Y-Y, Huang Y-L, Chang C, Kang H-Y. Deficiency in androgen receptor aggravates the depressive-like behaviors in chronic mild stress model of depression. *Cells* 2019;9:1021. <https://doi.org/10.3390/cells8091021>
75. Furuta M, Numakawa T, Chiba S, Ninomiya M, Kajiyama Y, Adachi N, Akema T, Kunugi H. Estrogen, predominantly via estrogen receptor α , attenuates postpartum-induced anxiety- and depression-like behaviors in female rats. *Endocrinology* 2013;10:3807-3816. <https://doi.org/10.1210/en.2012-2136>
76. Rocha BA, Fleischer R, Schaeffer JM, Rohrer SP, Hickey GJ. 17β -Estradiol-induced antidepressant-like effect in the Forced Swim Test is absent in estrogen receptor- β knockout (BERKO) mice. *Psychopharmacology* 2005;3:637-643. <https://doi.org/10.1007/s00213-004-2078-1>
77. Bastos CP, Pereira LM, Ferreira-Vieira TH, Drumond LE, Massensini AR, Moraes MF, Pereira GS. Object recognition memory deficit and depressive-like behavior caused by chronic ovariectomy can be transiently recovered by the acute activation of hippocampal estrogen receptors. *Psychoneuroendocrinology* 2015;57:14-25. <https://doi.org/10.1016/j.psyneuen.2015.03.020>
78. Walf AA, Frye CA. Administration of estrogen receptor beta-specific selective estrogen receptor modulators to the hippocampus decrease anxiety and depressive behavior of ovariectomized rats. *Pharmacol Biochem Behav* 2007;2:407-414. <https://doi.org/10.1016/j.pbb.2006.07.003>
79. Walf AA, Frye CA. A review and update of mechanisms of estrogen in the hippocampus and amygdala for anxiety and depression behavior. *Neuropsychopharmacology* 2006;6:1097-1111. <https://doi.org/10.1038/sj.npp.1301067>
80. Xu Y, Sheng H, Bao Q, Wang Y, Lu J, Ni X. NLRP3 inflammasome activation mediates estrogen deficiency-induced depression- and anxiety-like behavior and hippocampal inflammation in mice. *Brain Behav Immun* 2016;175:175-186. <https://doi.org/10.1016/j.bbi.2016.02.022>
81. Wang J, Yu R, Han Q-Q, Huang H-J, Wang Y-L, Li H-Y, Wang H-M, Chen X-R, Ma S-L, Yu J. G-1 exhibit antidepressant effect, increase of hippocampal ERs expression and improve hippocampal redox status in aged female rats. *Behav Brain Res* 2019;359:845-852. <https://doi.org/10.1016/j.bbr.2018.07.017>
82. Bopassa JC, Eghbali M, Toro L, Stefani E. A novel estrogen receptor GPER inhibits mitochondria permeability transition pore opening and protects the heart against ischemia-reperfusion injury. *Am J Physiol Heart Circ Physiol* 2010;1:H16-H23. <https://doi.org/10.1152/ajpheart.00588.2009>
83. Jia C, Brown RW, Malone HM, Burgess KC, Gill WD, Keasey MP, Hagg T. Ciliary neurotrophic factor is a key sex-specific regulator of depressive-like behavior in mice. *Psychoneuroendocrinology* 2019;100:96-105. <https://doi.org/10.1016/j.psyneuen.2018.09.038>
84. Hellgren C, Åkerud H, Skalkidou A, Bäckström T, Sundström-Poromaa I. Low serum allopregnanolone is associated with symptoms of depression in late pregnancy. *Neuropsychobiology* 2014;3:147-153. <https://doi.org/10.1159/000358838>
85. Almeida FB, Nin MS, Barros HMT. The role of allopregnanolone in depressive-like behaviors: Focus on neurotrophic proteins. *Neurobiol Stres* 2020;12:100218. <https://doi.org/10.1016/j.ynstr.2020.100218>
86. Schüle C, Nothdurfter C, Rupprecht R. The role of allopregnanolone in depression and anxiety. *Prog Neurobiol* 2014;79-87. <https://doi.org/10.1016/j.pneurobio.2013.09.003>
87. Frye CA, Walf AA. Changes in progesterone metabolites in the hippocampus can modulate open field and forced swim test behavior of proestrous rats. *Horm Behav* 2002;3:306-315. <https://doi.org/10.1006/hbeh.2002.1763>
88. Shirayama Y, Fujita Y, Oda Y, Iwata M, Muneoka K, Hashimoto K. Allopregnanolone induces antidepressant-like effects through BDNF-TrkB signaling independent from AMPA receptor activation in a rat learned helplessness model of depression. *Behav Brain Res* 2020;390:112670. <https://doi.org/10.1016/j.bbr.2020.112670>
89. Chen S, Gao L, Li X, Ye Y. Allopregnanolone in mood disorders: Mechanism and therapeutic development. *Pharmacol Res* 2021;169:105682. <https://doi.org/10.1016/j.phrs.2021.105682>
90. Bao A-M, Swaab DF. The human hypothalamus in mood disorders: the HPA axis in the center. *IBRO Rep* 2019;6:45-53. <https://doi.org/10.1016/j.ibror.2018.11.008>

91. Vamvakopoulos NC, Chrousos GP. Evidence of direct estrogenic regulation of human corticotropin-releasing hormone gene expression. Potential implications for the sexual dimorphism of the stress response and immune/inflammatory reaction. *J Clin Invest* 1993;4:1896-1902. <https://doi.org/10.1172/JCI116782>
92. Bao A, Fischer D, Wu Y, Hol E, Balesar R, Unmehopa U, Zhou J, Swaab D. A direct androgenic involvement in the expression of human corticotropin-releasing hormone. *Mol Psychiatry* 2006;6:567-576. <https://doi.org/10.1038/sj.mp.4001800>
93. Bibel M, Barde Y. Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. *Genes Dev* 2000;14:2919-2937. <https://doi.org/10.1101/gad.841400>
94. Berton O, McClung CA, DiLeone RJ, Krishnan V, Renthal W, Russo SJ, Graham D, Tsankova NM, Bolanos CA, Rios M, Monteggia LM, Self DW, Nestler EJ. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. *Science* 2006;311:1205-1209. <https://doi.org/10.1126/science.1120972>
95. Numakawa T, Odaka H, Adachi N. Actions of brain-derived neurotrophin factor in the neurogenesis and neuronal function, and its involvement in the pathophysiology of brain diseases. *Int J Mol Sci* 2018;11:3650. <https://doi.org/10.3390/ijms19113650>
96. Verhagen M, van der Meij A, van Deurzen PAM, Janzing JGE, Arias-Vásquez A, Buitelaar JK, Franke B. Meta-analysis of the BDNF Val66Met polymorphism in major depressive disorder: effects of gender and ethnicity. *Mol Psychiatry* 2010;3:260-271. <https://doi.org/10.1038/mp.2008.109>
97. von Richthofen S, Lang UE, Hellweg R. Effects of different kinds of acute stress on nerve growth factor content in rat brain. *Brain Res* 2003;2:207-213. [https://doi.org/10.1016/S0006-8993\(03\)03338-9](https://doi.org/10.1016/S0006-8993(03)03338-9)
98. Lange I, Meyer H. The gastrointestinal tract as target of steroid hormone action: quantification of steroid receptor mRNA expression (AR, ERalpha, ERbeta and PR) in 10 bovine gastrointestinal tract compartments by kinetic RT-PCR. *J Steroid Biochem Mol Biol* 2003;84:159-166. [https://doi.org/10.1016/S0960-0760\(03\)00025-6](https://doi.org/10.1016/S0960-0760(03)00025-6)
99. Campbell S, MacQueen G. The role of the hippocampus in the pathophysiology of major depression. *J Psychiatry Neurosci* 2004;6:417-426.
100. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. *Biol Psychiatry* 2008;6:527-532. <https://doi.org/10.1016/j.biopsych.2008.05.005>
101. Nomoto H, Baba H, Satomura E, Maeshima H, Takebayashi N, Namekawa Y, Suzuki T, Arai H. Serum brain-derived neurotrophic factor levels and personality traits in patients with major depression. *BMC Psychiatry* 2015;1:33. <https://doi.org/10.1186/s12888-015-0413-1>
102. Emon MPZ, Das R, Nishuty NL, Shalahuddin Qusar MMA, Bhuiyan MA, Islam MR. Reduced serum BDNF levels are associated with the increased risk for developing MDD: a case-control study with or without antidepressant therapy. *BMC Res Notes* 2020;1:83. <https://doi.org/10.1186/s13104-020-04952-3>
103. Mahmoud R, Wainwright SR, Galea LAM. Sex hormones and adult hippocampal neurogenesis: Regulation, implications, and potential mechanisms. *Front Neuroendocrinol* 2016;41:129-152. <https://doi.org/10.1016/j.yfrne.2016.03.002>
104. Ihara K, Yoshida H, Jones PB, Hashizume M, Suzuki Y, Ishijima H, Kim HK, Suzuki T, Hachisu M. Serum BDNF levels before and after the development of mood disorders: a case-control study in a population cohort. *Transl Psychiatr* 2016;4:e782-e782. <https://doi.org/10.1038/tp.2016.47>
105. Pedrotti Moreira F, Cardoso TC, Mondin TC, Wiener CD, de Mattos Souza LD, Oses JP, Jansen K, da Silva RA. Serum level of nerve growth factor is a potential biomarker of conversion to bipolar disorder in women with major depressive disorder. *Psychiatr Clin Neurosci* 2019;9:590-593. <https://doi.org/10.1111/pcn.12896>
106. Rasika S, Alvarez-Buylla A, Nottebohm F. BDNF Mediates the effects of testosterone on the survival of New Neurons in an adult brain. *Neuron* 1999;1:53-62. [https://doi.org/10.1016/S0896-6273\(00\)80678-9](https://doi.org/10.1016/S0896-6273(00)80678-9)
107. Espallergues J, Mamiya T, Vallée M, Koseki T, Nabeshima T, Tamsamani J, Laruelle C, Maurice T. The antidepressant-like effects of the 3 β -hydroxysteroid dehydrogenase inhibitor trilostane in mice is related to changes in neuroactive steroid and monoamine levels. *Neuropharmacology* 2012;1:492-502. <https://doi.org/10.1016/j.neuropharm.2011.09.005>

108. Su Q, Cheng Y, Jin K, Cheng J, Lin Y, Lin Z, Wang L, Shao B. Estrogen therapy increases BDNF expression and improves post-stroke depression in ovariectomy-treated rats. *Exp Ther Med* 2016;3:1843-1848. <https://doi.org/10.3892/etm.2016.3531>
109. Meltzer-Brody S, Colquhoun H, Riesenber g R, Epperson CN, Deligiannidis KM, Rubinow DR, Li H, Sankoh AJ, Clemson C, Schacterle A. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. *The Lancet* 2018;10152:1058-1070. [https://doi.org/10.1016/S0140-6736\(18\)31551-4](https://doi.org/10.1016/S0140-6736(18)31551-4)
110. Powell JG, Garland S, Preston K, Piszczatoski C. Brexanolone (Zulresso): Finally, an FDA-approved treatment for postpartum depression. *Ann Pharmacother* 2019;2:157-163. <https://doi.org/10.1177/1060028019873320>
111. Wirth M. Beyond the HPA axis: progesterone-derived neuroactive steroids in human stress and emotion. *Front Endocrinol (Lausanne)* 2011;2:19. <https://doi.org/10.3389/fendo.2011.00019>
112. Agis-Balboa RC, Guidotti A, Pinna G. 5 α -reductase type I expression is downregulated in the prefrontal cortex/Brodman's area 9 (BA9) of depressed patients. *Psychopharmacology* 2014;17:3569-3580. <https://doi.org/10.1007/s00213-014-3567-5>
113. Rasmusson AM, Pinna G, Paliwal P, Weisman D, Gottschalk C, Charney D, Krystal J, Guidotti A. Decreased cerebrospinal fluid allopregnanolone levels in women with posttraumatic stress disorder. *Biol Psychiatry* 2006;7:704-713. <https://doi.org/10.1016/j.biopsych.2006.03.026>
114. Romeo E, Ströhle A, Spalletta G, Michele Fd, Hermann B, Holsboer F, Pasini A, Rupprecht R. Effects of antidepressant treatment on neuroactive steroids in major depression. *Am J Psychiatry* 1998;7:910-913. <https://doi.org/10.1176/ajp.155.7.910>
115. Pinna G, Costa E, Guidotti A. Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. *Psychopharmacology* 2006;3:362-372. <https://doi.org/10.1007/s00213-005-0213-2>
116. Uzunova V, Sheline Y, Davis J, Rasmusson A, Uzunov D, Costa E, Guidotti A. Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. *Proc Natl Acad Sci U S A* 1998;6:3239-3244. <https://doi.org/10.1073/pnas.95.6.3239>
117. Romeo E, Pompili E, Michele Fd, Pace M, Rupprecht R, Bernardi G, Pasinib A. Effects of fluoxetine, indomethacine and placebo on 3 α , 5 α tetrahydroprogesterone (THP) plasma levels in uncomplicated alcohol withdrawal. *World J Biol Psychiatry* 2000;2:101-104. <https://doi.org/10.3109/15622970009150572>
118. Schüle C, Romeo E, Uzunov D, Eser D, Di Michele F, Baghai T, Pasini A, Schwarz M, Kempter H, Rupprecht R. Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3 α -hydroxysteroid dehydrogenase activity. *Mol Psychiatry* 2006;3:261-272. <https://doi.org/10.1038/sj.mp.4001782>
119. Ugale RR, Hirani K, Morelli M, Chopde CT. Role of neuroactive steroid allopregnanolone in antipsychotic-like action of olanzapine in rodents. *Neuropsychopharmacology* 2004;9:1597-1609. <https://doi.org/10.1038/sj.npp.1300460>
120. Prasad A. Efficacy of carbamazepine as an antidepressant in chronic resistant depressives. *J Indian Med Assoc* 1985;7:235-237.
121. Kobayashi T, Kishimoto A, Inagaki T. Treatment of periodic depression with carbamazepine. *Acta Psychiatr Scand* 1988;3:364-367. <https://doi.org/10.1111/j.1600-0447.1988.tb05137.x>
122. Kanes S, Colquhoun H, Gunduz-Bruce H, Raines S, Arnold R, Schacterle A, Doherty J, Epperson CN, Deligiannidis KM, Riesenber g R. Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. *Lancet* 2017;10093:480-489. [https://doi.org/10.1016/S0140-6736\(17\)31264-3](https://doi.org/10.1016/S0140-6736(17)31264-3)
123. Kanes SJ, Colquhoun H, Doherty J, Raines S, Hoffmann E, Rubinow DR, Meltzer-Brody S. Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression. *Hum Psychopharmacol Clin Exp* 2017;2:e2576. <https://doi.org/10.1002/hup.2576>
124. Meltzer-Brody S, Kanes SJ. Allopregnanolone in postpartum depression: Role in pathophysiology and treatment. *Neurobiol Stres* 2020;12:100212. <https://doi.org/10.1016/j.ynstr.2020.100212>
125. Chen CV, Jordan CL, Breedlove SM. Testosterone works through androgen receptors to modulate neuronal response to anxiogenic stimuli. *Neurosci Lett* 2021;753:135852. <https://doi.org/10.1016/j.neulet.2021.135852>

-
126. Sternbach H. Age-associated testosterone decline in men: clinical issues for psychiatry. *Am J Psychiatry* 1998;10:1310-1318. <https://doi.org/10.1176/ajp.155.10.1310>
 127. Khera M, Bhattacharya R, Blick Md G, Kushner H, Nguyen D, Miner M. The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS). *Aging Male* 2011;15:14-21. <https://doi.org/10.3109/13685538.2011.606513>
 128. Zarrouf FA, Artz S, Griffith J, Sirbu C, Kommor M. Testosterone and depression: systematic review and meta-analysis. *J Psychiatr Pract* 2009;4:289-305. <https://doi.org/10.1097/01.pra.0000358315.88931.fc>
 129. Amiaz R, Seidman SN. Testosterone and depression in men. *Curr Opin Endocrinol Diabetes Obes* 2008;3:278-283. <https://doi.org/10.1097/MED.0b013e3282fc27eb>
 130. Shores MM: Men's Health and Psychiatry. In: *Design and Implementation of the Modern Men's Health Center*. ALUKAL JP, LAMM S, WALSH TJ (eds), Springer Nature Switzerland, 2021, pp 231-248.
 131. Vartolomei MD, Kimura S, Vartolomei L, Shariat SF. Systematic review of the impact of testosterone replacement therapy on depression in patients with late-onset testosterone deficiency. *Eur Urol Focus* 2020;1:170-177. <https://doi.org/10.1016/j.euf.2018.07.006>
-